---
title: "ORAMED PHARMACEUTICALS INC. 1Q 2026: Revenue $0 Net income $38.31M, EPS $0.91— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286968146.md"
description: "Oramed Pharmaceuticals Inc. reported Q1 2026 results with $0 revenue and a net income of $38.31M, improving from a net loss of $(7.64) M in Q1 2025. Diluted EPS was $0.91, up from $(0.19) a year earlier. The company shifted to managing a medical technology portfolio, reduced R&D spending, and closed strategic transactions, including the Lifeward deal."
datetime: "2026-05-19T21:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286968146.md)
  - [en](https://longbridge.com/en/news/286968146.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286968146.md)
---

# ORAMED PHARMACEUTICALS INC. 1Q 2026: Revenue $0 Net income $38.31M, EPS $0.91— 10-Q Summary

Oramed Pharmaceuticals Inc. reported first-quarter 2026 results with no product revenue and a swing to net income of $38.31M versus a net loss of $(7.64) M in the year-ago quarter; diluted EPS was $0.91 for Q1 2026 compared with $(0.19) in Q1 2025.

**Financial Highlights**

-   Revenue was $0 for Q1 2026, down from $2.0M in Q1 2025.
-   Net income was $38.31M for Q1 2026, compared with a net loss of $(7.64) M in Q1 2025 (improvement of $45.95M).
-   Diluted EPS was $0.91 for Q1 2026, versus $(0.19) in Q1 2025.

**Business Highlights**

-   Revenue shift: The company recorded no product revenue in Q1 2026 as license-related revenue recognition declined versus $2.0M a year earlier.
-   Portfolio strategy: Oramed transitioned to an active operator of a medical technology portfolio, acquiring controlling stakes and managing clinical and regulatory strategy for portfolio companies.
-   Clinical & R&D: R&D spending was reduced after prior Phase 3 terminations; the company plans to intensify the ORA-D-013-3 trial via OraTech and continues to manage POD™ trials.
-   Strategic transactions: Closed the Lifeward deal transferring POD™ IP and received equity and warrants, plus secured a revenue-share arrangement on ReWalk products.
-   Operational milestones: Invested in Alpha Tau and Lifeward, supported multiple Alpha Tau FDA trials and obtained Japan Shonin approval for Alpha DaRT.

Original SEC Filing: ORAMED PHARMACEUTICALS INC. \[ ORMP \] - 10-Q - May. 19, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ORMP.US](https://longbridge.com/en/quote/ORMP.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [LFWD.US](https://longbridge.com/en/quote/LFWD.US.md)
- [DRTS.US](https://longbridge.com/en/quote/DRTS.US.md)
- [DRTSW.US](https://longbridge.com/en/quote/DRTSW.US.md)

## Related News & Research

- [embecta Completes Acquisition of Owen Mumford Holdings Limited](https://longbridge.com/en/news/286571686.md)
- [Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M](https://longbridge.com/en/news/286822028.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Gentoo Media publishes Q1 2026 interim report](https://longbridge.com/en/news/287169902.md)
- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)